Currently, the selection of CAR‐T cell targets predominantly relies on empirical tumor research, with notable examples including HER2,[46] EGFR,[47] and GPC3.[5] Additionally, there are studies investigating the combination of traditional and novel targets, such as the pairing of CD19 and GCC.[48, 49] These targets are typically identified through gene and protein expression studies of primary tumor transcriptomes. This evidence concerns the gene GUCY2C and neoplasm.